PLS1

Across TCGA pan-cancer cohorts, PLS1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PLS1 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLS1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLS1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and UCEC are the cancer types where PLS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.388	0.192	<.001	94	view →
COAD	DFS	Quartile	II,III,IV	1.000	0.860	.019	60	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.387	.011	30	view →
CCRCC	DFS	Quartile	All	1.000	0.489	.011	21	view →
LUAD	DFS	Quartile	II,III,IV	0.151	0.682	.021	4	view →
LSCC	OS	Quartile	All	0.892	1.000	.029	4	view →
HNSC	OS	Median	III,IV	0.789	0.581	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PLS1–PDAC (DFS)

Open the PDAC breakdown →